- Home
- ZYME vs DSGR Comparison
ZYME vs DSGR Comparison
Compare ZYME & DSGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- DSGR
- Stock Information
- Founded
- ZYME 2003
- DSGR 1952
- Country
- ZYME United States
- DSGR United States
- Employees
- ZYME N/A
- DSGR N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- DSGR Industrial Machinery/Components
- Sector
- ZYME Health Care
- DSGR Industrials
- Exchange
- ZYME Nasdaq
- DSGR Nasdaq
- Market Cap
- ZYME 1.2B
- DSGR 1.5B
- IPO Year
- ZYME 2017
- DSGR N/A
- Fundamental
- Price
- ZYME $16.56
- DSGR $28.27
- Analyst Decision
- ZYME Buy
- DSGR Buy
- Analyst Count
- ZYME 7
- DSGR 1
- Target Price
- ZYME $20.00
- DSGR $41.00
- AVG Volume (30 Days)
- ZYME 648.0K
- DSGR 70.2K
- Earning Date
- ZYME 10-30-2025
- DSGR 10-30-2025
- Dividend Yield
- ZYME N/A
- DSGR N/A
- EPS Growth
- ZYME N/A
- DSGR N/A
- EPS
- ZYME N/A
- DSGR 0.08
- Revenue
- ZYME $122,867,000.00
- DSGR $1,928,948,000.00
- Revenue This Year
- ZYME $107.76
- DSGR $11.30
- Revenue Next Year
- ZYME $2.35
- DSGR $4.13
- P/E Ratio
- ZYME N/A
- DSGR $308.07
- Revenue Growth
- ZYME 95.94
- DSGR 13.48
- 52 Week Low
- ZYME $9.03
- DSGR $21.87
- 52 Week High
- ZYME $17.70
- DSGR $41.47
- Technical
- Relative Strength Index (RSI)
- ZYME 57.31
- DSGR 33.94
- Support Level
- ZYME $16.75
- DSGR $29.18
- Resistance Level
- ZYME $17.40
- DSGR $30.56
- Average True Range (ATR)
- ZYME 0.58
- DSGR 1.06
- MACD
- ZYME -0.06
- DSGR -0.18
- Stochastic Oscillator
- ZYME 38.20
- DSGR 3.58
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.